Expanding Market Focus NAYA’s strategic shift to focus exclusively on fertility treatments and reproductive health, as evidenced by their separation from oncology and autoimmune divisions, presents a clear opportunity to develop specialized products or services tailored to reproductive clinics and healthcare providers in this niche.

Innovation in Fertility The company's emphasis on FDA-cleared INVOcell technology and novel fertility treatments positions it as a pioneer in reproductive health. Sales efforts could focus on partnerships, device upgrades, or training programs for clinics adopting or expanding these innovative solutions.

Significant Corporate Restructuring The recent reverse stock split, rebranding, and merger highlight NAYA’s efforts to streamline operations and strengthen market presence, creating openings for collaborative ventures, consulting services, and technology licensing opportunities.

Regulatory & Policy Impact Support for recent government initiatives to improve access to fertility treatments indicates favorable policy environments. Engaging with policy shift opportunities or funding programs for fertility clinics could open new sales channels or partnership avenues.

Financial & Market Position With revenue estimates between $10M and $25M and active expansion efforts, NAYA is positioned as an emerging leader in fertility pharmaceuticals and devices, suggesting opportunities to provide complementary technologies, support services, or new product lines to accelerate their growth trajectory.